Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DN022150 in KRAS G12D-mutant advanced solid tumors (Phase I/IIa)
ChiCTR2400088951Phase 2Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of DN-022150 in Nonhematologic neoplasms (7 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Adverse events (AE), Dose-limiting toxicity (DLT) and 1 more. Started Sep 2024; status: recruiting.
02
Drugs
DN-022150
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2400088951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088951.